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Abstract
Background: This study aimed to assess the effect of dehydroepiandrosterone (DHEA) plus climen (estradiol
valerate and cyproterone acetate drug combination) on infertility patients with diminished ovarian reserve (DOR)
and to determine if the combination of DHEA plus climen is superior to DHEA alone in improving ovarian response.
Methods: A total of 124 women were randomized into the DHEA group (n = 64) and the DHEA plus climen
group (n = 60) for 12 weeks before being subjected to in-vitro fertilization (IVF) cycles. To investigate if there is a
FSH-related difference on the effect of the addition of climen, the DHEA group and the DHEA plus climen group
were further divided into four subgroups according to a basal FSH level cut-off of 10 mIU/ml. We performed a
comparison of Day 3 blood samples before and after treatment and IVF outcome parameters, including AMH,
FSH, E2, AFC, oocytes retrieved, MII oocyte numbers, embryo numbers and accumulated embryo scores.
Results: After 12 weeks of pretreatment, the DHEA plus climen group demonstrated a significantly higher level of
AMH (P = 0.001) and a significantly lower level of FSH (P = 0.001) compared with the DHEA group. When the two
groups were divided into four subgroups based on the FSH cut-off of 10 mIU/mL, a significant increase of AMH
(P = 0.034) was found in the high-FSH DHEA plus climen group, whereas there was no significant difference in
the high-FSH DHEA group (P = 0.322). A significantly higher accumulated score of embryos was observed in the
low-FSH DHEA plus climen group compared with the low-FSH DHEA group (P = 0.034).
Conclusions: These observations suggest that patients with DOR of a low-FSH level might benefit more from
DHEA plus climen supplementation than from DHEA supplementation alone.
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Background
Dehydroepiandrosterone (DHEA), the body’s most abun-
dant circulating steroid substance, is produced by primar-
ily by the adrenal zona reticularis and ovarian theca cells
and functions as a precursor of testosterone and oestradiol
in the periphery [1]. The essential role of androgens is to
facilitate normal follicle development in the mouse. An-
drogens appear most engaged at the pre-antral and antral
stages, primarily affect granulosa cells, and exert effects
via androgen receptors (ARs), with ligand-activated AR
modulating follicle stimulating hormone (FSH) activity in
granulosa cells. Therefore, androgens serve as important
modulators of granulosa cell differentiation and follicle
maturation [2].
However, the effects of DHEA supplementation remain
controversial in humans because of a lack of large, well
designed, optimal quality randomized controlled trials
(RCTs). Previous studies [3–5] reported that the addition
of DHEA could improve oocyte and embryo yields, oocyte
and embryo quality, pregnancy rates and reduce miscar-
riage risk in patients with diminished ovarian reserve
(DOR). However, many of the early studies of DHEA sup-
plementation were not well accepted and/or were based
on observational data, and the results of those studies
were not free from bias. A recent RCT [6] revealed that
no statistically significant differences were found in the
ovarian response markers (AFC, AMH, or FSH) or IVF
outcomes between these two groups, although the serum
DHEA-S, free androgen index, and follicular DHEA-S
levels were significantly increased upon DHEA supple-
mentation. However, this study was limited by its small
sample size of 32 participants.
Given that experiments in rodents strongly support an
essential androgen function and there is a controversial
effect in humans, the current study continues to investi-
gate the use of DHEA and to determine the optimum
treatment regimen for patients with DOR.
Patients with DOR have a progressive decline in ovar-
ian oocyte quality and quantity, with an elevated basal
FSH level and a lower antral follicle count than patients
without DOR. Research has indicated that pretreatment
with oestrogen might inhibit concentrations of circulat-
ing FSH, restricting the depletion of follicles [7]. DHEA,
as described above, could up-regulate FSH receptors,
which might make remnant follicles more sensitive to
FSH administration. Climen (estradiol valerate and cy-
proterone acetate drug combination), which mimics the
function of oestrogen, could maintain the menstrual cycle
and does not inhibit ovulation. Therefore, we question if
DHEA/climen synergism could further augment the bene-
ficial effects of DHEA on ovarian reserve.
To evaluate this hypothesis, predictors of ovarian
reserve including serum AMH, FSH, and E2 of all pa-
tients were measured pre- and post-treatment in each
group. IVF cycle outcomes, including the number of oo-
cytes retrieved, MII oocytes, embryos and accumulated




This prospective study was conducted from July 2014 to
May 2015 at the Assisted Reproductive Center, The
Affiliated Hospital of Anhui Medical University. The study
was approved by the Clinical Research Ethics Committee
of The First Affiliated Hospital of Anhui Medical Univer-
sity (PJ-20140515) and Chinese Clinical Trial Register
(ChiCTR-TRC-14005030). Before the trial, the possible
effects of pretreatment and the trial were fully explained
to each participant and written consents were obtained.
We included infertility patients with diminished ovar-
ian reserve undergoing in vitro fertilization cycles. The
inclusion criteria for defining DOR in this study were
defined as follows: 1) an elevated day 3 (on the third
day of menstrual cycle) FSH level ≥10 mIU/mL or
FSH/LH >3; 2) an antral follicle count less than five; 3) a
previous poor ovarian response of retrieval of fewer than
five oocytes or cycle cancellation due to poor response to
ovarian stimulation. A diagnosis of DOR was reached if
the patient fulfilled any one of the above three criteria. Pa-
tients were excluded if they had any of the following: 1) a
history of ovarian cystectomy or oophorectomy; 2) a diag-
nosis of endometriosis; 3) a history of DHEA supplemen-
tation or hormonal replacement therapy; 4) abnormal
thyroid, liver or kidney function. Only Chinese women
were included in the study because DHEA acts mainly via
conversion to testosterone, and the rate of this conversion
could be quite different in different populations.
Participants were randomized in a 1:1 ratio according
to a computer-generated randomization sequence by a
study nurse and were allocated using sealed, opaque, se-
quentially numbered envelopes. Neither the study nurse
nor the participants would not know which group they
were in until the envelopes were opened by the studiers.
Patients in the DHEA group received a supplementation
of DHEA 25 mg three times per day. Patients in the
DHEA plus group would be supplemented with climen
(Climen, Bayer, German) 1 mg once per day.
Sample collection and determination
On the third day of the menstrual cycle (day 3), blood
samples were collected for the detection of serum AMH,
FSH, and E2 before the supplementation was started in
the groups. After 12 weeks of therapy prior to ovarian
stimulation, day 3 blood samples were collected again to
detect serum AMH, FSH, and E2, and the results were
compared with the samples collected prior to therapy.
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The serum samples were centrifuged at 2000 r/min for
15 min and stored at −80 °C until they were tested.
The concentration of AMH was determined by an
enzyme-linked immunosorbent assay (ELISA) [AMH:
AMH Gen II ELISA, ASNL, USA]. FSH and E2 levels
in serum were determined by a radioimmunoassay kit
(Beckman Coulter, Brea, USA).
Ovarian stimulation and embryo grade
After 12 weeks of DHEA or DHEA plus climen therapy,
patients with DOR were given 225 IU human meno-
pausal gonadotropin (HMG, Lizhu, China) from day 3 of
the cycle with 100 mg clomiphene citrate (CC, Lizhu,
China) once a day. Serial trans-vaginal scans were per-
formed using a 6.0 MHz vaginal probe (Toshiba SSA-
550A; Japan) to monitor the growth of follicles in both
ovaries. When at least one mature follicle with a mean
diameter ≥18 mm was observed on ultrasound, 10,000 IU
of human chorionic gonadotropin (HCG, Lizhu, China)
was administered, followed by trans-vaginal oocyte re-
trieval 36 h later. The participants would then undergo an
IVF or ICSI cycle depending on the quality of their part-
ner’s sperm.
Based on the percent fragmentation and cell counts,
embryos were graded from one to four on the third day
of incubation. Up to three of the best-quality embryos
were transferred on day 3. The accumulated score of
embryos was calculated by summing the score of each
embryo produced by each patient on the third day of
development. For example, a patient with two grade 4
embryos and one grade 3 embryo would be assigned a
score of 11. Patients with cycle cancellation would be
assigned a score of 0.
Clinical pregnancy
Fourteen days after the embryo transfer, a quantitative
pregnancy test (serum β-hCG) was taken. If positive, a
trans-vaginal ultrasound was performed 20 days later.
Clinical pregnancy was confirmed if a foetal heartbeat
was observed.
Statistical analyses
SPSS 17.0 was utilized for the data analysis. The data
were presented as the mean ± standard deviation (SD) or
as percentages. Quantitative variables were analysed with
Student’s t-test or the Mann-Whitney-U test, followed
by the one-sample Kolmogorov-Smirnov test. Quality
variables were analysed with the chi-square test. A two-
sided P < 0.05 was considered statistically significant.
Results
This study was conducted from July 2014 to May 2015.
During this period, a total of 147 patients fulfilled the cri-
teria of DOR and consented to participate this research.
After excluding discontinuers, 64 patients were exposed
to DHEA treatment, and 60 patients were exposed to
DHEA plus climen treatment for 12 weeks (See Fig. 1). All
women in this study underwent only one IVF or ICSI
cycle according to the quality of their spouse’s sperm.
As summarized in Table 1, the two groups were
homogeneous in terms of age, BMI, type of infertility
and infertility durations (P = 0.929, 0.644, 0.961 and
0.761, respectively). No significant difference was found
regarding the basal AMH, FSH, E2, and antral follicle
count (AFC), which represent ovarian reserve in the two
groups (P = 0.466, 0.343, 0.719 and 0.059, respectively).
As shown in Table 2, after 12 weeks of treatment with
DHEA plus climen, the mean serum AMH level was
significantly higher (0.90 ± 0.66 vs. 1.14 ± 0.79, P =0.001),
and the FSH level was significantly lower (11.86 ± 5.29
vs. 9.08 ± 5.51, P = 0.001) compared with pre-treatment
levels. However, a significantly higher level of E2 (160.65 ±
116.90 vs. 278.50 ± 135.80, P = 0.000) was observed in this
group compared with the pre-treatment level.
A comparison of ovarian reserve markers was made in
the DHEA group pre- and post-treatment. A significant in-
crease in the AMH (0.98 ± 0.72 vs. 1.24 ± 1.07, P = 0.015)
and a significant decrease in the FSH (12.93 ± 7.02 vs.
10.03 ± 5.48, P = 0.003) were observed in patients treated
with DHEA. The E2 level (181.53 ± 137.26 vs. 113.96 ±
70.00, P = 0.001) was significantly lower in this group after
treatment with DHEA (Table 2).
We monitored the concentration of DHEA-S and tes-
tosterone in this trial. DHEA-S and testosterone levels
were significantly higher after treatment in the DHEA +
climen group (1.14 ± 0.68 μg/mL vs. 4.73 ± 3.04 μg/
mL, P =0.00; 0.59 ± 0.51 nmol/L vs. 1.98 ± 1.14 nmol/L,
P =0.00) and in the DHEA group (1.15 ± 0.64 μg/mL vs.
5.35 ± 3.28 μg/mL, P =0.00; 0.63 ± 0.40 nmol/L vs. 2.05 ±
1.12 nmol/L, P =0.00).
To investigate if there is a different FSH-related effect,
the DHEA group and DHEA plus climen group were
further divided into four subgroups according to a basal
FSH level cut-off of 10 mIU/mL. Table 2 shows a signifi-
cantly higher level of AMH (0.68 ± 0.58 vs. 0.89 ± 0.75,
P = 0.034) in the high-FSH DHEA plus climen subgroup
post-treatment (n = 34), whereas there was no significant
difference in the high-FSH DHEA subgroup pre- and post-
treatment (0.88 ± 0.65 vs. 0.99 ± 1.06, P = 0.322; n = 36).
Both the DHEA group and the DHEA plus climen group
showed a significant decrease in FSH post-treatment.
A significantly higher level of AMH was observed in
the low-FSH DHEA plus climen subgroup (1.18 ± 0.67
vs. 1.45 ± 0.74, P = 0.004; n = 26) and in patients in
the low-FSH DHEA subgroup (1.11 ± 0.78 vs. 1.56 ± 1.01,
P = 0.002, n = 28). However, neither the DHEA group nor
the DHEA plus climen group showed significant changes
in the level of FSH after 12 weeks of treatment (Table 2).
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IVF cycle outcomes were compared as shown in Fig. 2.
Comparable effects including the number of oocytes
retrieved, MII oocytes, embryos and accumulated score
of embryos were observed in the DHEA plus climen
group and the DHEA group (P = 0.862, 0.355, 0.354 and
0.196, respectively; Fig. 2a). There were no significant
differences in the IVF outcomes between the two High-
FSH subgroups (Fig. 2b). However, a significantly higher
accumulated embryo score was observed in the low-FSH
DHEA plus climen group compared with the low-FSH
DHEA group (P = 0.034, Fig. 2c).
A total of 93 embryos (52 in the Low-FSH subgroup,
41 in the High-FSH subgroup) were achieved in the
DHEA + climen group, and 85 embryos were achieved in
the DHEA group (46 in the Low-FSH subgroup, 39 in
the High-FSH subgroup). The implantation rate of the
low-FSH DHEA + climen group was 17.31 % higher than
the Low-FSH DHEA group (13.04 %), although the dif-
ference was not statistically significant (P = 0.196). No
significant differences were found in the implantation
rates between the DHEA + climen group and the DHEA
group (16.13 vs. 12.94 %, P = 0.242) or between the two
High-FSH sub-groups (14.63 vs. 12.82 %, P = 0.446).
Fourteen clinical pregnancies (8 in the Low-FSH sub-
group, 6 in the High-FSH subgroup) were achieved in
the DHEA plus climen group after the IVF cycle, with a
pregnancy rate of 23.33 %. One pregnancy in the Low-
FSH subgroup was a twin pregnancy. In the DHEA
group, 11 patients (6 in the Low-FSH subgroup, 5 in the
High-FSH subgroup) conceived, with a pregnancy rate
of 17.19 %. There were no significant differences in the
pregnancy rates between the DHEA plus climen group
and the DHEA group (P = 0.616), between the two low-
Table 1 Comparison of baseline characters between the two
groups
The DHEA
group n = 64
The DHEA plus climen
group n = 60
P-value
Age (years) 37.06 ± 5.06 37.15 ± 5.80 0.929
BMI (kg/m2) 22.18 ± 2.73 22.39 ± 2.48 0.644
Primary infertility 42.19 % 42.67 % 0.961
Secondary infertility 57.81 % 57.33 %
Infertility
duration (years)
6.39 ± 4.10 6.65 ± 5.32 0.761
AMH (ng/ml) 0.98 ± 0.72 0.90 ± 0.66 0.466
FSH (IU/L) 12.93 ± 7.02 11.86 ± 5.29 0.343
E2 (pmol/L) 181.53 ± 137.26 160.65 ± 116.90 0.719
AFC 3.25 ± 2.07 3.47 ± 1.95 0.059
Data are presented as mean ± SD (standard deviation) or percentage
as appropriate
AFC the count of antral follicle
P < 0.05 was considered as statistically significant
Fig. 1 Flow diagram
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Table 2 Comparison of the ovarian reserve markers pre- and post-treatment in each group
The DHEA group P-value The DHEA plus climen group P-value
Pre-treament Post-treatment Pre-treament Post-treatment
AMH (ng/ml) 0.98 ± 0.72 1.24 ± 1.07 0.015 0.90 ± 0.66 1.14 ± 0.79 0.001
FSH(IU/L) 12.93 ± 7.02 10.03 ± 5.48 0.003 11.86 ± 5.29 9.08 ± 5.51 0.001
E2 (pmol/L) 181.53 ± 137.26 113.96 ± 70.00 0.001 160.65 ± 116.90 278.50 ± 135.80 0.000
High-FSH subgroups
AMH (ng/ml) 0.88 ± 0.65 0.99 ± 1.06 0.322 0.68 ± 0.58 0.89 ± 0.75 0.034
FSH (IU/L) 17.35 ± 6.34 11.84 ± 6.45 0.001 15.40 ± 4.00 10.56 ± 6.54 0.001
E2 (pmol/L) 155.70 ± 93.43 122.32 ± 79.44 0.070 120.35 ± 81.91 276.30 ± 139.76 0.000
Low-FSH subgroups
AMH (ng/ml) 1.11 ± 0.78 1.56 ± 1.01 0.002 1.18 ± 0.67 1.45 ± 0.74 0.004
FSH (IU/L) 7.24 ± 1.82 7.69 ± 2.49 0.445 7.13 ± 2.11 7.14 ± 2.87 0.982
E2 (pmol/L) 214.75 ± 174.96 103.21 ± 55.14 0.003 213.37 ± 135.26 281.53 ± 133.33 0.035
Data are presented as mean ± SD (standard deviation) or percentage as appropriate. Subgroups were divided based on a basal FSH level cut-off of 10 mlU/ml
P <0.05 was considered as statistically significant
Fig. 2 a Comparisons of IVF cycle outcomes between the DHEA plus climen group and the DHEA group. b Comparisons of IVF cycle outcomes
between the two high-FSH sub-groups. c Comparisons of IVF cycle outcomes between the two low-FSH sub-groups. *P <0.05
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FSH subgroups (P = 0.946) or between the two high-FSH
subgroups (P = 0.743).
In this study, we used CC +HMG, and the results are
limited to this treatment.
Discussion
Because patients with DOR are faced with limited
remaining reproductive life spans and live under great
pressure, treatments for these women need improvement
and increased evidence.
The rationale for this study was based on the hypoth-
esis that a chronically high FSH level in patients with
DOR down-regulates granulosa-cell FSH receptors,
causing the remaining follicles to become refractory to
exogenous stimulation. A study suggested that oestrogen
might increase the FSH receptors on granulosa-cells and
enhance the binding of FSH to its receptors [8].
Pretreatment with oestrogens in patients affected by pre-
mature ovarian failure down-regulated the level of FSH
and improved the rate of ovulation induction [9]. More-
over, researchers determined that pregnancy could be
achieved in patients with premature ovarian failure after
treatment with oestrogen plus progesterone [10]. Herein,
we substituted climen for the component oestrogen to
maintain the menstrual cycle.
Previous studies [11, 12] identified the potential role of
DHEA. Androgens play an essential role in normal fol-
licle maturation. Androgens primarily affect granulosa
cells and exert effects with ligand-activated ARs [11].
According to the two cell/two gonadotropin theory, it
has been postulated that DHEA could improve ste-
roidogenesis within the ovary because DHEA is a crucial
precursor steroid to human sex steroid synthesis [13].
DHEA plays an important role in the form of testosterone
and E2 in the periphery. Testosterone and its metabolite
5α-dehydrotestosterone (DHT) are the best agonists
for the ARs compared with other androgens [14].
Up-regulated ARs further modulate FSH activities in
granulosa cells and modulates follicle maturation [2].
Granulosa cells respond to FSH and induce changes in an-
drogen metabolism. There appears to be a feedback loop
between androgens and FSH. Therefore, DHEA serves as
an important modulator of follicle maturation.
In animal models, follicle recruitment is under the
synergism of FSH/androgen [15]. In humans, researchers
have observed that repeated short (<120 days) interval
exposure to DHEA resulted in increased oocyte yield
across three consecutive IVF cycles. This observation
suggested that patients with DOR might take advantage
of a possible DHEA/FSH synergism [16].
To evaluate the effect of DHEA plus climen on ovar-
ian reserve, serum AMH, FSH, and E2 were detected in
the present study. The serum AMH and FSH levels
and the number of antral follicles are the three most
frequently used predictors for ovarian reserve prior to
IVF cycles in clinical practice [17]. Furthermore,
AMH is the single best marker predicting ovarian re-
sponse to gonadotropins and defines low versus good
live-birth chances in women with severely diminished
ovarian reserve independent of age [18].
There was a significantly higher level of AMH and a
significantly lower level of FSH in the patients treated
with DHEA plus climen. Animal experiments demon-
strated that the expression of AR mRNA was positively
correlated with the expression of FSH receptor mRNA.
Moreover, the expression of AR mRNA showed a posi-
tive association with the AMH receptor. Therefore, the
increase of AMH and the decrease of FSH in our study
are understandable results [19].
Similarly, comparable effects including a significant in-
crease in AMH and a significant decrease in FSH were
observed in the DHEA group. This result is consistent
with previous studies. Yilmaz reported a significant dif-
ference in all of the parameters after at least 6 weeks of
DHEA treatment [20]. Neeta Singh obtained a similar
result after studying 30 patients with a history of poor
response. These women were treated with DHEA for
4 months longer than previous study. A significant in-
crease in serum AMH levels and a significant decrease
in Day 2 FSH levels were observed in all age groups (35,
36–38 and >38 years) [21]. However, no statistically sig-
nificant change was detected in the antral follicle count.
A recent RCT observed no significant differences in
serum FSH and AMH levels between the DHEA group
and the placebo group throughout the study period,
although this result is not in agreement with previous
studies [6]. However, the level of follicular DHEA-S was
significantly higher in the DHEA group. Follicular AMH
was also higher in the DHEA group, although the in-
crease did not reach statistical significance.
A significant increase in E2 was observed in the DHEA
plus climen group, whereas the level was significantly
lower in patients after treatment with DHEA. This result
might be interpreted as the exogenous complement of
climen because E2 is the combination of oestradiol valer-
ate and cyproterone acetate.
Both subgroups with low FSH level demonstrated a
significant increase in AMH. However, neither group
showed a significant change in FSH. These results are
expected because the patients within these two sub-
groups had normal FSH values lower than 10 mIU/ml
and were diagnosed with DOR because of a history of a
poor response or an antral follicle count of less than five.
The increased AMH indicated the effect of DHEA plus
climen group on patients with normal FSH.
Both sub-groups with high FSH level showed a signi-
ficant decrease in the level of FSH. However, only the pa-
tients in the DHEA plus climen group had a significant
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change in the level of AMH. Moreover, a significantly
higher level of accumulated embryo score was observed in
the low-FSH DHEA plus climen group compared with the
low-FSH DHEA group. Despite the small size of our study
group, the differences between the groups are marked.
Conclusions
DHEA plus climen supplementation prior to in-vitro
fertilization (IVF) cycles might have better effects than
DHEA alone for infertility patients with diminished ovar-
ian reserve of low-FSH level.
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